EPILEPSY AFFECTS NEARLY 2 MILlion
|
|
- Marian Harvey
- 5 years ago
- Views:
Transcription
1 SCIENTIFIC REVIEW AND CLINICAL APPLICATIONS CLINICIAN S CORNER The New Antiepileptic Drugs Clinical Applications Suzette M. LaRoche, MD Sandra L. Helmers, MD EPILEPSY AFFECTS NEARLY 2 MILlion people in the United States. 1 Despite many recent surgical advances, medications remain the mainstay of treatment. Approximately 70% of patients with epilepsy will become seizure-free using a single antiepileptic drug. 2 For the remaining 30%, recurrent seizures as well as intolerable adverse effects can have significant impact on quality of life. In the last decade, 8 new antiepileptic drugs have been approved for therapy, broadening treatment options and providing hope for improved seizure control and tolerability. The initial diagnostic evaluation and treatment of patients with new-onset seizures are complex and should be undertaken by a neurologist or epilepsy specialist. The first diagnostic goal is to confirm that the events in question are epileptic seizures and if so, whether partial or generalized in onset (FIGURE). A detailed history and description of the events in question given by the patient as well as a witness is crucial. Electroencephalography (EEG) and magnetic resonance imaging (MRI) aid in the classification of the seizure type and help assess for any underlying structural lesions that could be contributing to the onset of seizures. Finally, patient history, neurological examination findings, and results of diagnostic tests are also taken into account to classify the patient as having a particular epilepsy syndrome, which has implications for treatment as well as prognosis. See also p 605 and Patient Page. In the past decade, 8 new antiepileptic drugs have been approved for use in the United States, offering many new treatment options to patients with epilepsy. With expanding use of these newer agents, primary care clinicians are challenged with understanding the roles that each new agent plays in the treatment of patients with epilepsy as well as possible interactions with other pharmacological therapies. Each new medication provides a unique profile of pharmacokinetics, adverse effects, and mechanisms of action, making an appreciation of how these agents are best utilized even more difficult. Despite well-performed trials evaluating the safety and efficacy of specific antiepileptic drugs, the lack of head-to-head comparisons among them makes it difficult to endorse a single therapeutic regimen. Limited studies have compared the new antiepileptic drugs with more traditional medications and found similar efficacy but improved tolerability of the newer agents. There remains no well-established guidelines for choosing a particular antiepileptic drug or for choosing a newer agent over a traditional one. However, careful consideration of seizure type, patient comorbidities, and specific medication toxicities aids in prescribing the most appropriate medication. This article aims to familiarize the general practitioner with the appropriate roles and effective uses of the new antiepileptic drugs in specific clinical scenarios. JAMA. 2004;291: Once the seizure type and epilepsy syndrome have been determined, an antiepileptic drug can be appropriately selected. All of the new antiepileptic drugs are efficacious for partial-onset seizures and were originally approved based on their efficacy as add-on therapy in patients with refractory partial-onset seizures. For patients with generalized-onset seizures the choice of therapy is narrower and includes valproate as well as the newer agents lamotrigine and topiramate. Ultimately, medication choice is tailored to the individual patient. Specific considerations should include adverse effect profile, drug interactions, and pharmacokinetics (TABLE 1). Dosing schedule and cost contribute significantly to patient compliance and are important factors to consider as well (TABLE 2). The following cases demonstrate some of the unique advantages of the newer antiepileptic drugs to familiarize the clinician with why each of the new agents may be chosen in a particular clinical situation. For more information, resources are available for physicians as well as patients (BOX). Author Affiliations: Department of Neurology, Emory University (Drs LaRoche and Helmers), and Atlanta VA Medical Center (Dr LaRoche), Atlanta, Ga. Corresponding Author and Reprints: Suzette M. LaRoche, MD, Emory Clinic, Bldg A, 1365 Clifton Rd, Atlanta, GA ( American Medical Association. All rights reserved. (Reprinted) JAMA, February 4, 2004 Vol 291, No
2 CLINICAL CASES Case 1 A 22-year-old woman, otherwise healthy, presents with a 6-month history of episodes of unresponsiveness accompanied by lip smacking lasting 1 to 2 minutes and occurring 2 to 3 times per month. She takes no medications. She is in a monogamous relationship with a male sexual partner and only occasionally uses contraception. A routine EEG shows left temporal epileptiform activity and MRI of the brain shows left mesial temporal sclerosis. One of the most challenging populations of epilepsy patients is women of childbearing age. Many issues must be considered, including contraception, pregnancy, and bone health. Most of the traditional anticonvulsant medications Figure. Algorithm for Diagnosis and Treatment of Recurrent Seizures Focal Seizures Simple Partial Complex Partial Secondary Generalized Select Antiepileptic Drug Traditional Carbamazepine Mysoline Phenobarbital Phenytoin Valproate Newer Gabapentin Lamotrigine Topiramate Tiagabine Levetiracetam Oxcarbazepine Zonisamide Yes Classify Seizure Type Select Antiepileptic Drug Traditional Ethosuximide (Absence Seizures Only) Valproate Newer Lamotrigine Topiramate Zonisamide Diagnostic Evaluation History Neurological Examination Electroencephalography (EEG) Magnetic Resonance Imaging EEG-Video Monitoring Does This Patient Have Epileptic Seizures? Generalized Seizures Absence Tonic Clonic Tonic-Clonic Myoclonic Atonic Possible Epilepsy No Other Diagnosis Physiologic Syncope Migraine Sleep Disturbance Transient Ischemic Attack Psychologic Conversion Disorder Anxiety Disorder Attention-Deficit/Hyperactivity Disorder enhance the metabolism of oral contraceptives, resulting in an increased risk of unexpected pregnancy, although the use of formulations with higher estrogen content may help reduce this risk. 3,4 On the contrary, many of the new antiepileptic drugs have not been shown to have any effect on the metabolism of oral contraceptives, with the exception of felbamate, topiramate, and oxcarbazepine. 5-7 The treatment of epilepsy during pregnancy has always presented a unique challenge that should be managed by a specialist. Congenital malformations occur in 4% to 6% of infants born to women with epilepsy, twice that of the general population, with even higher rates in women taking more than 1 antiepileptic drug. 8 Evidence supports the use of antiepileptic drugs as the cause for these teratogenic effects. 9,10 Recent studies have shown the incidence of congenital malformations to be increased in the offspring of women taking phenobarbital, phenytoin, carbamazepine, and valproate monotherapy and therefore each is classified as pregnancy category D. 9,11 Further data are being collected from the North American Antiepileptic Drug Pregnancy Registry, which is designed to measure the teratogenic effects of all antiepileptic drugs (Box). Early data released from the registry demonstrate the strongest evidence of a link between congenital malformations and antiepileptic drug exposure. Infants exposed to valproate monotherapy had an 8.8% incidence of major birth defects (n=123; 95% confidence interval [CI], 3.09%-9.55%), and those exposed to phenobarbital monotherapy experienced a 6.3% incidence (n=79; 95% CI, 2.1%-14.2%) compared with 1.6% of controls. 12 There have been insufficient data collected on the teratogenic effects of the new antiepileptic drugs; therefore, each is classified as pregnancy category C. However, the Lamotrigine Pregnancy Registry has been collecting data from women with exposure to lamotrigine during the first trimester and preliminary results have recently been published. 13 A total of 168 women taking lamotrigine monotherapy were followed up, with a resultant 1.8% incidence of major birth defects, comparable to rates in the general population. Further data are being collected to more conclusively evaluate the safety of lamotrigine as well as the other new antiepileptic drugs in pregnancy. Although the exact mechanism of teratogenesis is unknown, folate deficiency is thought to be a major contributing factor. Serum and red blood cell folate levels have been found to be decreased in women taking phenobarbital as well as phenytoin, particularly in combination. 14 Various mechanisms have been proposed to explain the antifolate effects of antiepileptic drugs, including decreased intestinal ab- 616 JAMA, February 4, 2004 Vol 291, No. 5 (Reprinted) 2004 American Medical Association. All rights reserved.
3 sorption, induction of hepatic enzymes, and inhibition of folate synthesis, although the exact mechanism is unknown. 15 The effects of the newer antiepileptic drugs on folate metabolism have not been evaluated; however, the lack of induction of hepatic enzymes by most of the new medications may suggest minimal interference. Nevertheless, folate supplementation is recommended for all women of childbearing age taking any antiepileptic drug. Finally, phenobarbital, phenytoin, and carbamazepine have been associated with decreased bone mineral density Although many theories have been proposed, the principal mechanism is thought to be induction of hepatic enzymes leading to increased catabolism of vitamin D. 16,19 However, a recent study demonstrated a link between valproate, a hepatic enzyme inhibitor, and bone loss, suggesting that other mechanisms may be involved. 20 No studies have been performed evaluating the effect of any of the new antiepileptic drugs on bone density, although lack of induction of hepatic enzymes suggests a possible benefit over the conventional antiepileptic drugs. In this particular case, history as well as EEG and MRI findings confirm that this patient is experiencing recurrent partial-onset seizures, likely of left temporal lobe origin. Her history of sporadic contraception favors choosing an antiepileptic drug with the lowest teratogenecity. Although there are still insufficient numbers of exposures to consider lamotrigine completely safe in pregnancy, early data appear favorable. 13 In addition, lamotrigine does not cause induction of the cytochrome P450 system and does not interact with oral contraceptives. 21,22 This patient should Table 1. Comparison of Traditional and Newer Antiepileptic Drugs Antiepileptic Drug Protein Binding, % Metabolism Advantages Disadvantages Traditional agents Carbamazepine 80 Hepatic Extensive patient exposure Drug interactions, hyponatremia Phenobarbital 50 Hepatic Inexpensive, once-daily dosing Sedation, cognitive effects Phenytoin 90 Hepatic Inexpensive, once-daily dosing Nonlinear kinetics, drug interactions Valproate 95 Hepatic Broad spectrum Weight gain, tremor, hair loss Newer agents Felbamate 25 Hepatic Broad spectrum Risk of aplastic anemia, hepatotoxicity Gabapentin 10 Renal No drug interactions, rapid titration Sedation, weight gain Lamotrigine 55 Hepatic Broad spectrum, favorable adverse effect profile Slow titration, rash Topiramate 15 Hepatic/renal Broad spectrum Slow titration, cognitive effects, kidney stones Tiagabine 95 Hepatic Novel mechanism of action Multiple doses per day, tremor Levetiracetam 10 Renal No drug interactions, rapid titration Rare behavioral changes Oxcarbazepine 50 Hepatic Less neurotoxic adverse effects than carbamazepine Hyponatremia risk Zonisamide 40 Hepatic Broad spectrum, once-daily dosing Slow titration, anorexia Table 2. Dosing and Cost Comparison Antiepileptic Drug Starting Daily Dose, mg* Daily Dosing Interval Average Daily Maintenance Dose, mg Titration Schedule Monthly Cost, $ Traditional agents Carbamazepine Times 1200 Slow Phenobarbital 60 Once 150 Slow 2.70 Phenytoin 300 Once 300 Rapid Valproate Times 2000 Rapid Newer agents Gabapentin Times 2400 Rapid Lamotrigine 50 Twice 400 Slow Added to valproate 25 (Every other day) Twice Slow Topiramate Twice 400 Slow Tiagabine Times 48 Slow Levetiracetam 1000 Twice 1500 Rapid Oxcarbazepine 600 Twice 1200 Slow Zonisamide 100 Once 200 Slow *As recommended by each manufacturer s package insert. Rapid titration indicates maintenance dose achieved in less than 2 weeks; slow titration, an average of 2 to 12 weeks required to achieve maintenance dose. Brand name prices from the 2002 Drug Topics Red Book. Retail prices may be higher or lower depending on the pharmacy and patient s insurance coverage American Medical Association. All rights reserved. (Reprinted) JAMA, February 4, 2004 Vol 291, No
4 Box. Physician and Patient Resources Epilepsy Foundation of America American Epilepsy Society Antiepileptic Drug Pregnancy Registry /aed/ Lamotrigine Pregnancy Registry also start daily folate supplementation. Case 2 A 65-year-old man with a history of hypertension, atrial fibrillation, hypercholesterolemia, and a right middle cerebral artery stroke 6 months previous reports 3 separate episodes of head deviation to the left with rhythmic jerking of the left arm and left side of his face lasting approximately 1 minute. He is taking warfarin, atenolol, and atorvastatin. Elderly individuals have the highest incidence of epilepsy across age groups, approaching nearly twice that of childhood. 23,24 Common underlying causes of epilepsy in this population include stroke, neurodegenerative disease, and brain neoplasm. Therefore, neuroimaging is critical in the evaluation of these patients. However, up to half of these patients have no specific identifiable underlying cause. 23 Physiological changes associated with aging as well as concomitant illnesses and resultant polypharmacy pose particular challenges in the treatment of epilepsy in the elderly population. In addition, elderly individuals have been shown to be more susceptible to the neurotoxic effects of antiepileptic drugs, including gait disturbance, sedation, and tremor. 25 Fortunately, seizures in elderly persons are usually easily treated with a single agent at low therapeutic doses. There are limited studies on the effects of the new antiepileptic drugs in the elderly population. Two studies compared gabapentin and lamotrigine with carbamazepine in elderly patients and found equal efficacy but better tolerability in the patients taking gabapentin or lamotrigine. 26,27 The lack of significant drug interactions in addition to low protein binding seen in the majority of the new antiepileptic drugs, particularly gabapentin and levetiracetam, suggest a benefit of these medications in the elderly population. 28,29 Stroke is the most common identifiable cause for the development of partialonset seizures in elderly individuals, as is demonstrated in this particular case. 23 The onset of seizures can occur immediately following the stroke or months to years later with the risk of recurrence as high as 50%. 30,31 In this patient, minimizing drug interactions is of utmost importance, especially in the setting of warfarin therapy. Lamotrigine has been shown to have a favorable adverse effect profile in this population, with minimal drug interactions, and would therefore be a good consideration as initial therapy. Gabapentin has not been definitively shown to be efficacious as monotherapy in younger, refractory study populations and therefore is currently approved only for adjunctive use. However, minimal central nervous system adverse effects and the lack of drug interactions coupled with the fact that seizures in the elderly population are typically more responsive to medication than are traditional study populations make gabapentin an attractive option for elderly patients with seizures. 32 In fact, a recent survey of experts in the field of epilepsy showed that gabapentin is often prescribed as monotherapy in the elderly population. 33 Likewise, levetiracetam, which has not been evaluated in randomized controlled trials as monotherapy, is often used in the elderly population by the same field of epilepsy experts because of a similar, very favorable pharmacokinetic profile and lack of toxicity. 32,33 Case 3 A 21-year-old obese man who is otherwise healthy reports a 5-year history of generalized tonic-clonic seizures that occur approximately 2 to 3 times per year. A routine EEG shows occasional generalized spike and slow-wave discharges. Findings on MRI of the brain are normal. He has been taking valproate since the onset of the seizures but is noncompliant and complains of lethargy as well as a tremor in both hands when taking the medication as prescribed. Generalized-onset seizures are most effectively treated with broad-spectrum antiepileptic drugs. For many years, valproate was the only broad-spectrum agent available and is still considered first-line therapy by many experts for generalized-onset seizures. 33 Unfortunately, its use has the potential for intolerable adverse effects, which include weight gain, tremor, hair loss, and lethargy. 34,35 Valproate has also been associated with neural tube defects in the offspring of women who take it during pregnancy as well as rare cases of hepatotoxicity and acute pancreatitis Lamotrigine and topiramate are both effective in the treatment of generalizedonset seizures and neither has been associated with systemic organ toxicities. Rash is the most serious potential adverse effect of lamotrigine and is seen predominantly in children, patients taking concurrent valproate, and with rapid titration. 39 Patients starting lamotrigine therapy who develop a rash should seek medical attention. Topiramate has been associated with modest weight loss, averaging 1 to 6 kg, as well as rare cases of nephrolithiasis and recently reported angle-closure glaucoma, which occurs early in the course of therapy and reverses rapidly with discontinuation of the drug Topiramate also has the potential for causing cognitive dysfunction, specifically language disturbances, although this complication may be related to dosage and titration schedule. 40,43,44 In this particular patient, the EEG finding of generalized epileptiform discharges confirms the diagnosis of generalized epilepsy. Medication noncompliance is likely contributing to breakthrough seizures; thus, switching to another antiepileptic drug may im- 618 JAMA, February 4, 2004 Vol 291, No. 5 (Reprinted) 2004 American Medical Association. All rights reserved.
5 prove compliance as well as seizure control. Topiramate offers the potential for weight loss in this obese patient with potentially fewer adverse effects. Although currently not approved for monotherapy, topiramate has shown efficacy as a single agent in a placebocontrolled trial enrolling 80 patients with primary generalized tonic-clonic seizures. In that study, 56% of patients experienced a 50% or greater reduction in seizures (P=.001). 45 Because lethargy was a reason for previous noncompliance, lamotrigine could be considered an option since it has been shown to be associated with less sedation than traditional antiepileptic drugs. 46,47 Case 4 A 45-year-old woman presents with a long history of partial-onset seizures. She is currently taking carbamazepine, 800 mg/d, which has decreased her seizure frequency remarkably but she continues to have a complex partial seizure every 2 to 3 months. Higher doses of carbamazepine have resulted in dizziness, ataxia, and diplopia. It is not uncommon for a patient to experience an incomplete response to a modest dosage of an antiepileptic drug but not tolerate dose increases due to adverse effects. This patient has responded to carbamazepine but has far from complete seizure control. Because increasing the dose of her current antiepileptic drug is not possible, there are 2 options: switch to a different agent or add an additional agent as adjunctive therapy. Oxcarbazepine is an analogue of carbamazepine but with the advantage of fewer adverse effects due to its lack of formation of a toxic metabolite. 48 Switching this patient from carbamazepine to oxcarbazepine monotherapy would potentially allow for increasing to higher doses and improve seizure control without the addition of adverse effects. Potential adverse effects include hyponatremia, although it is usually largely asymptomatic and seen mostly in elderly persons and in patients taking concomitant diuretics. 49 Any of the new antiepileptic drugs could be used as adjunctive therapy in combination with carbamazepine; however, choosing an antiepileptic drug with a different mechanism of action would provide more comprehensive coverage. Topiramate, tiagabine, and zonisamide offer unique mechanisms of action but require a slow titration schedule of at least 4 weeks to reach target maintenance doses. Gabapentin and levetiracetam have minimal interaction with other medications including carbamazepine and can be initiated more rapidly, reaching effective doses within 1 to 2 weeks. 50,51 CONCLUSIONS Physicians now have more pharmaceutical options for treating epilepsy than ever before. Although this has led to more complex decision making for practitioners, it has given patients greater hope for seizure control without intolerable adverse effects. Despite a lack of direct comparisons among the new antiepileptic drugs and between the new and traditional agents, informed choices can still be made. Primary care clinicians should have an understanding of the important advantages as well as adverse effects and drug interactions that accompany the new antiepileptic drugs and guide treatment choices. Initial studies show the new agents to be equally efficacious but overall better tolerated than traditional agents. In addition, most of the new agents have a more favorable pharmacokinetic profile with limited hepatic metabolism and fewer drug interactions. Finally, many of the newer agents offer a broader spectrum of activity. Ultimately, the choice of an antiepileptic drug should be tailored to the individual patient to accomplish seizure freedom without medication toxicity. REFERENCES 1. Hauser WA, Annegers JF, Kurland LT. The prevalence of epilepsy in Rochester, Minnesota, Epilepsia. 1991;32: Mattson RH, Cramer JA, Collins JF, et al. A comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonicclonic seizures. N Engl J Med. 1985;313: Back DJ, Bates M, Breckenridge BA, et al. The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy. Contraception. 1980;22: Mattson RH, Cramer JA, Darney PD, et al. Use of oral contraceptives by women with epilepsy. JAMA. 1986;256: Rosenfeld W, Doose DR, Walker SA, et al. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia. 1997;38: Fattore C, Gatti GC, Limido GL, et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia. 1999;40: Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs. 2002;16: Yerby MS, Leavitt A, Erickson DM, et al. Antiepileptics and the development of congenital malformations. Neurology. 1992;42(suppl 5): Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med. 2001; 344: Canger R, Battino D, Canerini M, et al. Malformations in the offspring of women with epilepsy: a prospective study. Epilepsia. 1999;40: Samren EB, van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia. 1997;38: Holmes L, Wyszynski D, Mittendorf R, et al. Evidence for an increased risk of birth defects in the offspring of women exposed to valproate: findings from the AED pregnancy registry [abstract]. Am J Obstet Gynecol. 2002;187: Tennis P, Eldridge RR, and The International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Preliminary results on pregnancy outcomes in women using lamotrigine. Epilepsia. 2002;43: Dansky LV, Andermann E, Andermann F, et al. Anticonvulsants, folate levels, and pregnancy outcome: a prospective study. Ann Neurol. 1987;21: Dansky LV, Rosenblatt DS, Andermann E. Mechanisms of teratogenesis: folic acid and antiepileptic therapy. Neurology. 1992;42(suppl 5): Valimaki MJ, Tiihonen M, Laitinen K, et al. Bone mineral density measured by dual-energy X-ray absorptiomety and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res. 1994;9: Tomita S, Ohnishi J-I, Nakano M, et al. The effects of anticonvulsant drugs on vitamin D3- activating cytochrome P-450-linked monooxygenase systems. J Steroid Biochem Mol Biol. 1991;39: Feldkamp J, Becker A, Witte OW, et al. Long-term anticonvulsant therapy leads to low bone mineral density: evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes. 2000;108: Pack AM, Morrell MJ. Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms, and therapeutic implications. CNS Drugs. 2001; 15: Sato Y, Kondo I, Ishida S, et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology. 2001;57: Gilliam FG, Gidal BE. Lamotrigine. In: Wyllie E, ed. The Treatment of Epilepsy. 3rd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001: Holdrich T, Whiteman P, Orme M, et al. Effect of lamotrigine on pharmacology of the combined oral contraceptive pill [abstract]. Epilepsia. 1992;32 (suppl 1): Hauser WA, Annegers JF, Kurland L. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: Epilepsia. 1993;34: American Medical Association. All rights reserved. (Reprinted) JAMA, February 4, 2004 Vol 291, No
6 24. Loiseau J, Loiseau P, Duche B, et al. A survey of epileptic disorders in southwest France: seizures in elderly patients. Ann Neurol. 1990;27: Ramsay RE, Rowan AJ, Slater JD, et al. Effect of age on epilepsy and its treatment: results from the VA Cooperative study [abstract]. Epilepsia. 1994;35 (suppl 8): Martin R, Meador K, Turrentine L, et al. Comparative cognitive effects of carbamazepine and gabapentin in healthy senior adults. Epilepsia. 2001;42: Brodie MJ, Overstall PW, Giorgi L, et al. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Res. 1999;37: Radtke R. Pharmacokinetics of levetiracetam. Epilepsia. 2001;42(suppl 4):S24-S Radulovic LL, Wilder BJ, Leppik IE, et al. Lack of interaction of gabapentin with carbamazepine and valproate. Epilepsia. 1994;35: Hauser WA, Rich SS, Annegers JF, et al. Seizure recurrence after a 1st unprovoked seizure: an extended follow-up. Neurology. 1990;40: Lamy C, Domigo V, Semah F, et al. Early and late seizures after cryptogenic ischemic stroke in young adults. Neurology. 2003;60: Willmore J. Choice of newer anticonvulsant drugs in older patients. Drugs Aging. 2000;17: Karceski S, Morrell MJ, Carpenter D. The expert consensus guideline series: treatment of epilepsy. Epilepsy Behavior. 2001;2:A1-A Dinesen H, Gram L, Anderson T, et al. Weight gain during treatment with valproate. Acta Neurol Scand. 1984;70: Bourgeois B. Valproate. In: Wyllie E, ed. The Treatment of Epilepsy. 3rd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001: Lindhout D, Meinhardi H. Spina bifida and in utero exposure to valproate. Lancet. 1984;2: Dreifuss FR, Santilli N, Langer DH, et al. Valproic acid hepatic fatalities: a retrospective view. Neurology. 1987;37: Physicians Desk Reference. 56th ed. Montvale, NJ: Medical Economics Co; Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia. 1999;40: Shorvon S. Safety of topiramate: adverse events and relationships to dosing. Epilepsia. 1996;37 (suppl 2):S18-S Wasserstein AG, Rak I, Reife RA. Nephrolithiasis during treatment with topiramate [abstract]. Epilepsia. 1995;36(suppl 3):S Asconape J. Some common issues in the use of antiepileptic drugs. Semin Neurol. 2002;22: Ojemann LM, Ojemann GA, Dodrill CB, et al. Language disturbances as side effects of topiramate and zonisamide therapy. Epilepsy Behavior. 2001;2: Lee S, Sziklas V, Andermann F, et al. The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia. 2003;44: Biton V, Montouris GD, Ritter F, et al, for the Topiramate YTC Study Group. A randomized, placebocontrolled study of topiramate in primary generalized tonic-clonic seizures. Neurology. 1999;52: Brodie MJ, Richen A, Yuen AWC, for the UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet. 1995; 345: Steiner TJ, Dellaportas CI, Findley LJ. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia. 1999;40: Wong IC, Lhatoo SD. Adverse reactions to new anticonvulsant drugs. Drug Saf. 2000;23: Friis ML, Kristensen O, Boas J, et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand. 1993;87: Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure. 2000;9: Fisher RS, Sachdeo R, Pellock J, et al. Rapid initiation of gabapentin: a randomized, controlled trial. Neurology. 2001;56: The art of art, the glory of expression and the sunshine of the light of letters is simplicity. Walt Whitman ( ) 620 JAMA, February 4, 2004 Vol 291, No. 5 (Reprinted) 2004 American Medical Association. All rights reserved.
Epilepsy and EEG in Clinical Practice
Mayo School of Professional Development Epilepsy and EEG in Clinical Practice November 10-12, 2016 Hard Rock Hotel at Universal Orlando Orlando, FL Course Directors Jeffrey Britton, MD and William Tatum,
More informationWhen choosing an antiepileptic ... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs. Based on a presentation by Barry E.
... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs Based on a presentation by Barry E. Gidal, PharmD Presentation Summary A physician s choice of an antiepileptic drug (AED) usually depends
More informationReview of Anticonvulsant Medications: Traditional and Alternative Uses. Andrea Michel, PharmD, CACP
Review of Anticonvulsant Medications: Traditional and Alternative Uses Andrea Michel, PharmD, CACP Objectives Review epidemiology of epilepsy Classify types of seizures Discuss non-pharmacologic and pharmacologic
More informationEpilepsy is a very individualized
... PRESENTATION... Treatment of Epilepsy in 3 Specialized Populations Based on a presentation by Ilo E. Leppik, MD Presentation Summary When discussing the treatment of epilepsy, targeted populations
More informationEpilepsy: problems of diagnosis and recommended treatment Nicola Cooper MRCP and Morgan Feely MD, FRCP, FRCP(I)
Epilepsy: problems of diagnosis and recommended treatment Nicola Cooper MRCP and Morgan Feely MD, FRCP, FRCP(I) VM Our series Prescribing in gives practical advice for successful management of the special
More informationPrescribing and Monitoring Anti-Epileptic Drugs
Prescribing and Monitoring Anti-Epileptic Drugs Mark Granner, MD Clinical Professor and Vice Chair for Clinical Programs Director, Iowa Comprehensive Epilepsy Program Department of Neurology University
More information11b). Does the use of folic acid preconceptually decrease the risk of foetal malformations in women with epilepsy?
updated 2012 Management of epilepsy in women of child bearing age Q11: 11a). In women with epilepsy, should antiepileptic therapy be prescribed as monotherapy or polytherapy to decrease the risk of fetal
More informationMONOTHERAPY IS PREferred
Monotherapy in Epilepsy Role of the Newer Antiepileptic Drugs Blanca Vazquez, MD NEUROLOGICAL REVIEW Background: Monotherapy is the goal for pharmacological treatment of epilepsy. Well-controlled trials
More informationEpilepsy 7/28/09! Definitions. Classification of epilepsy. Epidemiology of Seizures and Epilepsy. International classification of epilepsies
Definitions Epilepsy Dr.Yotin Chinvarun M.D., Ph.D. Seizure: the clinical manifestation of an abnormal and excessive excitation of a population of cortical neurons Epilepsy: a tendency toward recurrent
More informationAnticonvulsants Antiseizure
Anticonvulsants Antiseizure Seizure disorders Head trauma Stroke Drugs (overdose, withdrawal) Brain tumor Encephalitis/ Meningitis High fever Hypoglycemia Hypocalcemia Hypoxia genetic factors Epileptic
More informationPROCEEDINGS PHARMACOLOGIC TREATMENT CONSIDERATIONS * Dennis J. Dlugos, MD ABSTRACT
PHARMACOLOGIC TREATMENT CONSIDERATIONS * Dennis J. Dlugos, MD ABSTRACT A number of traditional and newer antiepileptic drugs (AEDs) are used for the initial treatment of new-onset epilepsy. The decision-making
More informationChapter 31-Epilepsy 1. public accountant, and has begun treatment with lamotrigine. In which of the following activities
Chapter 31-Epilepsy 1 Chapter 31. Epilepsy, Self-Assessment Questions 1. BW is a 28-year-old man recently diagnosed with partial seizures. He works as a certified public accountant, and has begun treatment
More information2018 American Academy of Neurology
Practice Guideline Update Efficacy and Tolerability of the New Antiepileptic Drugs I: Treatment of New-Onset Epilepsy Report by: Guideline Development, Dissemination, and Implementation Subcommittee of
More informationAlthough the prevalence of epilepsy and
NEW-ONSET EPILEPSY IN WOMEN: AN INDICATION FOR A NEWER ANTIEPILEPTIC DRUG? Jeffrey Cohen, MD, PhD* ABSTRACT Seizure patterns are often related to the reproductive cycles of a woman with epilepsy. Seizures
More informationEpilepsy T.I.A. Cataplexy. Nonepileptic seizure. syncope. Dystonia. Epilepsy & other attack disorders Overview
: Clinical presentation and management Markus Reuber Professor of Clinical Neurology Academic Neurology Unit University of Sheffield, Royal Hallamshire Hospital. Is it epilepsy? Overview Common attack
More informationCLINICIAN INTERVIEW AS i M: When you examine a clinical trial in new- onset epilepsy, how relevant are the results to your daily clinical practice?
FROM CLINICAL TRIALS TO CLINICAL PRACTICE: TRANSLATING EPILEPSY RESEARCH INTO PATIENT CARE Interview with Jacqueline A. French, MD Dr Jacqueline A. French is a Professor in the Department of Neurology
More informationTreatment of epilepsy in adults
Treatment of epilepsy in adults Review 33 Treatment of epilepsy in adults S B Gunatilake 1, A Arasalingam 2 Sri Lanka Journal of Neurology, 2012, 1, 33-38 Case vignettes 1. A 60-year old patient with long
More informationObjectives. Amanda Diamond, MD
Amanda Diamond, MD Objectives Recognize symptoms suggestive of seizure and what those clinical symptoms represent Understand classification of epilepsy and why this is important Identify the appropriate
More informationPregnancy and Epilepsy
Pregnancy and Epilepsy Nowhere is the problem more evident or more complicated than in pregnancy. In the United States, epilepsy affects nearly one million women of childbearing potential. Alarm bells
More informationNew antiepileptic drugs
Chapter 29 New antiepileptic drugs J.W. SANDER UCL Institute of Neurology, University College London, National Hospital for Neurology and Neurosurgery, Queen Square, London, and Epilepsy Society, Chalfont
More informationDisclosure. Learning Objectives
Linda D. Leary, M.D. Associate Clinical Professor of Pediatrics & Neurology South Texas Comprehensive Epilepsy Center UT Health Science Center San Antonio Disclosure Linda D. Leary, M.D. discloses the
More informationSelection of Anti-Epileptic Medication in Newly Diagnosed Epilepsy
Selection of Anti-Epileptic Medication in Newly Diagnosed Epilepsy S Venkataraman *, CS Narayanan ** * Senior Consultant Neurologist, Mata Chanan Devi Hospital, New Delhi; ** Classified Specialist (Medicine
More informationThe Effectiveness of Monotheraby in Epileptic Sudanese Patients
The Effectiveness of Monotheraby in Epileptic Sudanese Patients Amel Elmahi Mohamed (1) Sawsan A Aldeaf (1) Alsadig Gassoum (1) Alnada Abdalla Mohamed (2) Mohamed A Arbab (1,3) and Alamin Ebrahim (2) Abstract
More informationMedications for Epilepsy What I Need to Know
Medications for Epilepsy What I Need to Know Safiya Ladak, BSc.Phm. Toronto Western Hospital, UHN Clinical Pharmacist, Neurology and Neurosurgery June 4, 2016 Learning Objectives Treatment options for
More informationTeratogenic Effects of Antiepileptic Medications
Teratogenic Effects of Antiepileptic Medications Torbj rn Tomson, MD, PhD a,b, *, Dina Battino, MD c KEYWORDS Epilepsy Pregnancy Antiepileptic drugs Teratogenicity Birth defects It has been estimated that
More informationAED Treatment Approaches. David Spencer, MD Director, OHSU Epilepsy Center Professor, Department of Neurology
AED Treatment Approaches David Spencer, MD Director, OHSU Epilepsy Center Professor, Department of Neurology Audience Response Keypads Please utilize the keypad at your table to answer questions throughout
More informationDisclosures. Objectives 2/16/2015. Women with Epilepsy: Seizures in Pregnancy and Maternal/Fetal Outcomes
Women with Epilepsy: Seizures in Pregnancy and Maternal/Fetal Outcomes 40 th Annual Progress in OBGYN February 19, 2015 Jennifer L. DeWolfe, DO Associate Professor UAB Epilepsy Center Director, BVAMC Sleep
More information11/7/2018 EPILEPSY UPDATE. Dr.Ram Sankaraneni. Disclosures. Speaker bureau LivaNova
EPILEPSY UPDATE Dr.Ram Sankaraneni Disclosures Speaker bureau LivaNova 1 Outline New onset Seizure Investigations in patients with epilepsy Medical management of epilepsy Non Pharmacological options in
More informationWHY CHILDREN ARE DIFFERENT FROM ADULTS
XXASIM May p159-165 5/14/01 9:23 AM Page 159 NEW PHARMACOLOGICAL TREATMENTS FOR PEDIATRIC EPILEPSY Blaise F.D. Bourgeois, MD KEY POINTS Antiepileptic drugs (AEDs) are tailored to pediatric epilepsy seizure
More information2011 MNA Midwest Summer Conference
2011 MNA Midwest Summer Conference Women and Epilepsy Marianna V. Spanaki, M.D., Ph.D., M.B.A. SENIOR STAFF NEUROLOGIST DIRECTOR EPILEPSY MONITORING UNIT HENRY FORD COMPREHENSIVE EPILEPSY PROGRAM HENRY
More informationRecommendations. for Care of Adults with Epilepsy. Seeking the best treatment from the right doctor at the right time!
Recommendations for Care of Adults with Epilepsy Seeking the best treatment from the right doctor at the right time! Contents This booklet is to help adults and their caregivers know when it is appropriate
More informationManagement of Epilepsy in Primary Care and the Community. Carrie Burke, Epilepsy Specialist Nurse
Management of Epilepsy in Primary Care and the Community Carrie Burke, Epilepsy Specialist Nurse Epilepsy & Seizures Epilepsy is a common neurological disorder characterised by recurring seizures (NICE,
More informationEpilepsy 101. Overview of Treatment Kathryn A. O Hara RN. American Epilepsy Society
Epilepsy 101 Overview of Treatment Kathryn A. O Hara RN American Epilepsy Society Objectives Describe the main treatment options for epilepsy Identify factors essential in the selection of appropriate
More informationDefining refractory epilepsy
Defining refractory epilepsy Pasiri S, PMK Hospital @ 8.30 9.00, 23/7/2015 Nomenclature Drug resistant epilepsy Medically refractory epilepsy Medical intractable epilepsy Pharmacoresistant epilepsy 1 Definition
More informationDavid Dredge, MD MGH Child Neurology CME Course September 9, 2017
David Dredge, MD MGH Child Neurology CME Course September 9, 2017 } 25-40,000 children experience their first nonfebrile seizure each year } AAN/CNS guidelines developed in early 2000s and subsequently
More informationAN UPDATE ON ANTIEPILEPTIC AGENTS: FOCUS ON AN UPDATE ON ANTIEPILEPTIC AGENTS: FOCUS ON SECOND GENERATION TREATMENT OPTIONS
Volume 24, Issue 1 October 2008 AN UPDATE ON ANTIEPILEPTIC AGENTS: FOCUS ON SECOND GENERATION TREATMENT OPTIONS Jason Richey, Pharm.D. Candidate Epilepsy is a neurological disorder characterized by sudden
More informationErnie Somerville Prince of Wales Hospital EPILEPSY
Ernie Somerville Prince of Wales Hospital EPILEPSY Overview Classification New and old anti-epileptic drugs (AEDs) Neuropsychiatric side-effects Limbic encephalitis Non-drug therapies Therapeutic wishlist
More informationManagement of Epilepsy in Pregnancy
Management of Epilepsy in Pregnancy September 7, 2018 Stephanie Paolini, MD Clinical Instructor/Women s Neurology Fellow UPMC Neurology We ve come a long way Sterilization of people with epilepsy was legal
More informationModified release drug delivery system for antiepileptic drug (Formulation development and evaluation).
TITLE OF THE THESIS / RESEARCH: Modified release drug delivery system for antiepileptic drug (Formulation development and evaluation). INTRODUCTION: Epilepsy is a common chronic neurological disorder characterized
More informationTeratogenic and other considerations in the selection of antiepileptic drugs in girls and women
3 rd Congress of the European Academy of Neurology Amsterdam, The Netherlands, June 24 27, 2017 Teaching Course 7 Treatment of women with epilepsy - Level 1-2 Teratogenic and other considerations in the
More informationInformation on the risks of Valproate (Epilim) use in girls (of any age), women of childbearing potential and pregnant women.
CONTAINS NEW INFORMATION GUIDE FOR HEALTHCARE PROFESSIONALS Information on the risks of Valproate (Epilim) use in girls (of any age), women of childbearing potential and pregnant women. Read this booklet
More informationUpdated advice for nurses who care for patients with epilepsy
NICE BULLETIN Updated advice for nurses who care for patients with epilepsy NICE provided the content for this booklet which is independent of any company or product advertised NICE BULLETIN Updated advice
More informationOpinion 24 July 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 24 July 2013 FYCOMPA 2 mg, film-coated tablet B/7 (CIP: 34009 267 760 0 8) B/28 (CIP: 34009 268 447 4 5) FYCOMPA 4
More informationp ผศ.นพ.ร งสรรค ช ยเสว ก ล คณะแพทยศาสตร ศ ร ราชพยาบาล
Natural Course and Prognosis of Epilepsy p ผศ.นพ.ร งสรรค ช ยเสว ก ล คณะแพทยศาสตร ศ ร ราชพยาบาล Introduction Prognosis of epilepsy generally means probability of being seizure-free after starting treatment
More informationIntroduction. 1 person in 20 will have an epileptic seizure at some time in their life
Introduction 1 person in 20 will have an epileptic seizure at some time in their life Epilepsy is diagnosed on the basis of two or more epileptic seizures. Around 450,000 people in the UK have epilepsy
More informationDoes a diagnosis of epilepsy commit patients to lifelong therapy? Not always. Here s how to taper AEDs safely and avoid relapse.
Does a diagnosis of epilepsy commit patients to lifelong therapy? Not always. Here s how to taper AEDs safely and avoid relapse. T he epilepsy specialist always has two equally important endpoints in mind
More informationEpilepsy. Seizures and Epilepsy. Buccal Midazolam vs. Rectal Diazepam for Serial Seizures. Epilepsy and Seizures 6/18/2008
Seizures and Epilepsy Paul Garcia, M.D. UCSF Epilepsy Epileptic seizure: the physical manifestation of aberrant firing of brain cells Epilepsy: the tendency to recurrent, unprovoked epileptic seizures
More informationChoice of antie. which one to try fi rst an REVIEW
6 PRACTICAL NEUROLOGY REVIEW Choice of antie which one to try fi rst an Margaret J Jackson Consultant Neurologist, Department of Neurology, Royal Victoria Infi rmary, Newcastle upon Tyne, NE1 4LP; E-mail:
More informationThe New England Journal of Medicine EARLY IDENTIFICATION OF REFRACTORY EPILEPSY. Patients
EARLY IDENTIFICATION OF REFRACTORY EPILEPSY PATRICK KWAN, M.D., AND MARTIN J. BRODIE, M.D. ABSTRACT Background More than 30 percent of patients with epilepsy have inadequate control of seizures with drug
More informationThe Evaluation and Management of Seizures
Introduction The Evaluation and Management of Seizures Elizabeth Waterhouse, M.D. Associate Professor Department of Neurology Virginia Commonwealth University School of Medicine 1 Evaluating a single seizure
More informationAPPENDIX K Pharmacological Management
1 2 3 4 APPENDIX K Pharmacological Management Table 1 AED options by seizure type Table 1 AED options by seizure type Seizure type First-line AEDs Adjunctive AEDs Generalised tonic clonic Lamotrigine Oxcarbazepine
More informationEPILEPSY: SPECTRUM OF CHANGE WITH AGE. Gail D. Anderson, Ph.D.
EPILEPSY: SPECTRUM OF CHANGE WITH AGE Gail D. Anderson, Ph.D. Incidence: 0.5% - 1.0% of U.S. population Peak incidence of onset: first 2 years of life, ages 5-7 years, early puberty and elderly. 125,000
More informationlevetiracetam 250,500,750 and 1000mg tablets and levetiracetam oral solution 100mg/1ml (Keppra ) (No. 397/07) UCB Pharma Ltd
Scottish Medicines Consortium Resubmission levetiracetam 250,500,750 and 1000mg tablets and levetiracetam oral solution 100mg/1ml (Keppra ) (No. 397/07) UCB Pharma Ltd 11 January 2008 The Scottish Medicines
More informationLevetiracetam monotherapy in juvenile myoclonic epilepsy
Seizure (2008) 17, 64 68 www.elsevier.com/locate/yseiz Levetiracetam monotherapy in juvenile myoclonic epilepsy Deron V. Sharpe *, Anup D. Patel, Bassel Abou-Khalil, Gerald M. Fenichel Vanderbilt University
More informationTreatment Options for Seizures: Practical Points in Epilepsy Management
Lehigh Valley Health Network LVHN Scholarly Works Neurology Update for the Non-Neurologist 2013 Neurology Update for the Non-Neurologist Feb 20th, 8:10 PM - 8:40 PM Treatment Options for Seizures: Practical
More informationPRACTICE PARAMETER MANAGEMENT ISSUES FOR WOMEN WITH EPILEPSY (SUMMARY STATEMENT)
PRACTICE PARAMETER MANAGEMENT ISSUES FOR WOMEN WITH EPILEPSY (SUMMARY STATEMENT) Report of the Quality Standards Subcommittee of the American Academy of Neurology Overview. The Quality Standards Subcommittee
More informationTherapeutic strategies in the choice of antiepileptic drugs
Acta neurol. belg., 2002, 102, 6-10 Original articles Therapeutic strategies in the choice of antiepileptic drugs V. DE BORCHGRAVE, V. DELVAUX, M. DE TOURCHANINOFF, J.M. DUBRU, S. GHARIANI, Th. GRISAR,
More informationWomen s Issues in Epilepsy. Esther Bui, Epilepsy Fellow MD, FRCPC
Women s Issues in Epilepsy Esther Bui, Epilepsy Fellow MD, FRCPC How are women different? Different habitus Different metabolism Different co-morbidities Different psychosocial stigma Different hormonal
More informationOptimizing Management of Seizure Disorders
708 Medicine Update 121 Optimizing Management of Seizure Disorders V NAGARAJAN INTRODUCTION Seizure disorders are met with by every consultant in practice almost everyday. In the management of seizure
More informationMonitoring and Antiepileptic Drug Safety
Practice Monitoring and Antiepileptic Drug Safety L. James Willmore, MD, FAAN, FANA ABSTRACT Treatment of patients with epilepsy strives for complete seizure control without intolerable drug side effects.
More informationKeywords: treatment; epilepsy; population based cohort Institute of Neurology, University College London, London WC1N 3BG, UK
632 Institute of Neurology, University College London, London WC1N 3BG, UK S D Lhatoo JWASSander S D Shorvon Correspondence to: Professor J W Sander, Department of Clinical and Experimental Epilepsy, Institute
More informationPharmacy Medical Necessity Guidelines: Anticonvulsants/Mood Stabilizers
Pharmacy Medical Necessity Guidelines: Anticonvulsants/Mood Stabilizers Effective: December 18, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review
More informationDifficult to treat childhood epilepsy: Lessons from clinical case scenario
Difficult to treat childhood epilepsy: Lessons from clinical case scenario Surachai Likasitwattanakul, M.D. Department of Pediatrics Faculty of Medicine, Siriraj Hospital Natural history of Epilepsy Untreated
More informationOn completion of this chapter you should be able to: list the most common types of childhood epilepsies and their symptoms
9 Epilepsy The incidence of epilepsy is highest in the first two decades of life. It falls after that only to rise again in late life. Epilepsy is one of the most common chronic neurological condition
More informationThere are several types of epilepsy. Each of them have different causes, symptoms and treatment.
1 EPILEPSY Epilepsy is a group of neurological diseases where the nerve cell activity in the brain is disrupted, causing seizures of unusual sensations, behavior and sometimes loss of consciousness. Epileptic
More informationUpdate in Clinical Guidelines in Epilepsy
Why We Need Clinical Guidelines? Clinician needs advice! Update in Clinical Guidelines in Epilepsy Charcrin Nabangchang, M.D. Phramongkutklao College of Medicine Tiamkao S, Neurology Asia2013 Why We Need
More informationEpilepsy and Epileptic Seizures
Epilepsy and Epileptic Seizures Petr Marusič Dpt. of Neurology Charles University, Second Faculty of Medicine Motol University Hospital Diagnosis Steps Differentiation of nonepileptic events Seizure classification
More informationIntroduction to seizures and epilepsy
Introduction to seizures and epilepsy Selim R. Benbadis, M.D. Professor Departments of Neurology & Neurosurgery Director, Comprehensive Epilepsy Program Symptomatic seizures Head injury (trauma) Stroke
More informationNew Medicines Profile
New Medicines Profile February 2010 Issue No. 10/02 Eslicarbazepine Concise evaluated information to support the managed entry of new medicines in the NHS Brand Name, (Manufacturer): Zebinix (Eisai Limited)
More informationNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE. Final Appraisal Determination. Newer drugs for epilepsy in children
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE 1 Guidance 1.1 The newer antiepileptic drugs gabapentin, lamotrigine, oxcarbazepine, tiagabine, topiramate, and vigabatrin (as an adjunctive therapy for partial
More informationEpilepsy management What, when and how?
Epilepsy management What, when and how? J Helen Cross UCL-Institute of Child Health, Great Ormond Street Hospital for Children, London, & National Centre for Young People with Epilepsy, Lingfield, UK What
More informationOXCARBAZEPINE. THERAPEUTICS Brands Trileptal see index for additional brand names. Generic? Yes
OXCARBAZEPINE THERAPEUTICS Brands Trileptal see index for additional brand names Generic? Yes Class Anticonvulsant, voltage-sensitive sodium channel antagonist Commonly Prescribed for (bold for FDA approved)
More information2018 American Academy of Neurology
Practice Guideline Update Efficacy and Tolerability of the New Antiepileptic Drugs II: Treatment-Resistant Epilepsy Report by: Guideline Development, Dissemination, and Implementation Subcommittee of the
More informationار ناج هکنآ مان هب تخومآ
فکرت را جان آنکه به نام آموخت صرع در حاملگی بیش از 90 درصد مادران مصروع می توانند فرزندان طبیعی داشته باشند Are antiepileptic drugs necessary? What effect do antiepileptic drugs have on the fetus? What
More informationBirth Rate among Patients with Epilepsy: A Nationwide Population-based Cohort Study in Finland
American Journal of Epidemiology Copyright 2004 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 159, No. 11 Printed in U.S.A. DOI: 10.1093/aje/kwh140 Birth Rate among Patients
More informationCase 1: Issues in this case. Generalized Seizures. Seizure Rounds with S.Khoshbin M.D. Disclosures: NONE
Disclosures: NONE Seizure Rounds with S.Khoshbin M.D. Case 1: 45 yo male while jogging with his wife stopped,acted strangely for a while then fell to the ground and had a convulsion.emt s were called by
More informationRefractory epilepsy: treatment with new antiepileptic drugs
Seizure 2000; 9: 51 57 doi: 10.1053/seiz.1999.0348, available online at http://www.idealibrary.com on Refractory epilepsy: treatment with new antiepileptic drugs P. K. DATTA & P. M. CRAWFORD Department
More informationScottish Medicines Consortium
Scottish Medicines Consortium levetiracetam, 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra ) No. (394/07) UCB Pharma Limited 10 August 2007 The Scottish Medicines Consortium
More informationTRANSPARENCY COMMITTEE OPINION. 19 July 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 July 2006 Keppra 250 mg, film-coated tablets Box of 60 tablets (CIP code: 356 013-6) Keppra 500 mg, film-coated
More informationPharmacological Treatment of Non-Lesional Epilepsy December 8, 2013
Pharmacological Treatment of Non-Lesional Epilepsy December 8, 2013 Michael Privitera, MD Professor of Neurology University of Cincinnati, Neuroscience Institute American Epilepsy Society Annual Meeting
More informationRetrospective study of topiramate in a paediatric population with intractable epilepsy showing promising effects in the West syndrome patients
Acta neurol. belg., 2000, 100, 171-176 Retrospective study of topiramate in a paediatric population with intractable epilepsy showing promising effects in the West syndrome patients J. THIJS, H. VERHELST,
More informationEpilepsy in dementia. Case 1. Dr. Yotin Chinvarun M..D. Ph.D. 5/25/16. CEP, PMK hospital
Epilepsy in dementia Dr. Yotin Chinvarun M..D. Ph.D. CEP, PMK hospital Case 1 M 90 years old Had a history of tonic of both limbs (Lt > Rt) at the age of 88 years old, eye rolled up, no grunting, lasting
More informationeslicarbazepine acetate 800mg tablet (Zebinix) SMC No. (592/09) Eisai Ltd
eslicarbazepine acetate 800mg tablet (Zebinix) SMC No. (592/09) Eisai Ltd 8 October 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards
More informationSuccessful treatment of super-refractory tonic status epilepticus with rufinamide: first clinical report
*Manuscript Click here to view linked References Successful treatment of super-refractory tonic status epilepticus with rufinamide: first clinical report Thompson AGB 1, Cock HR 1,2. 1 St George s University
More informationAnnex III. Amendments to relevant sections of the summary of product characteristics and package leaflets
Annex III Amendments to relevant sections of the summary of product characteristics and package leaflets Note: These amendments to the relevant sections of the Summary of Product Characteristics and package
More informationEpilepsy 101. Russell P. Saneto, DO, PhD. Seattle Children s Hospital/University of Washington November 2011
Epilepsy 101 Russell P. Saneto, DO, PhD Seattle Children s Hospital/University of Washington November 2011 Specific Aims How do we define epilepsy? Do seizures equal epilepsy? What are seizures? Seizure
More informationBenefits and risks of taking antiepileptic medicine for females Information for healthcare professionals
Benefits and risks of taking antiepileptic medicine for females Information for healthcare professionals 2 Benefits and risks of taking antiepileptic medicine for females 3 This booklet provides information
More informationThe Epilepsy Prescriber s Guide to Antiepileptic Drugs
The Epilepsy Prescriber s Guide to Antiepileptic Drugs The Epilepsy Prescriber s Guide to Antiepileptic Drugs Philip N. Patsalos FRCPath, PhD Professor of Clinical Pharmacology and Consultant Clinical
More informationThe Selection of Antiepileptic Drugs for the Treatment of Epilepsy in Children and Adults
The Selection of Antiepileptic Drugs for the Treatment of Epilepsy in Children and Adults Jorge J. Asconape, MD KEYWORDS Epilepsy Seizures Antiepileptic drugs Epilepsy is one of the most common chronic
More informationJeffrey W Boyle, MD, PhD Avera Medical Group Neurology Sioux Falls, SD
Jeffrey W Boyle, MD, PhD Avera Medical Group Neurology Sioux Falls, SD Disclosures: None Objectives Recognize the incidence of seizure and epilepsy in the US population Appreciate the differences in seizure
More informationEfficacy of Levetiracetam: A Review of Three Pivotal Clinical Trials
Epilepsia, 42(Suppl. 4):31 35, 2001 Blackwell Science, Inc. International League Against Epilepsy Efficacy of : A Review of Three Pivotal Clinical Trials Michael Privitera University of Cincinnati Medical
More informationZONISAMIDE THERAPEUTICS. Brands * Zonegran. Generic? Not in US. If It Doesn t Work * Class Antiepileptic drug (AED), structurally a sulfonamide
Z:/3-PAGINATION/SBT/2-PROOFS/NWMS/9780521136723C111//9780521136723C111.3D 376 [376 380] ZONISAMIDE Brands Zonegran Generic? Not in US THERAPEUTICS Class Antiepileptic drug (AED), structurally a sulfonamide
More information7/31/09. New AEDs. AEDs. Dr. Yotin Chinvarun M.D. Ph.D. Comprehensive Epilepsy and Sleep disorder Program PMK hospital. 1 st genera*on AEDs
Dr. Yotin Chinvarun M.D. Ph.D. Comprehensive Epilepsy and Sleep disorder Program PMK hospital New AEDs AEDs NEW OLD Pregabalin Pregabalin 1 st genera*on AEDs Phenytoin Carbamazepine Valproate Phenobarbital
More informationManagement of Epilepsy in Older People Christine J Kilpatrick, Adrian J Lowe
REGERIATRIC THERAPEUTICS Editors: Dr Michael Woodward, Director of Aged Care Services, Dr Juli Moran, Consultant Geriatrician, Dr Margaret Bird, Consultant Geriatrician, Mr Rohan Elliott, Clinical Pharmacist,
More informationCLINICIAN INTERVIEW FACING THE CHALLENGES OF EPILEPSY TREATMENT. An interview with William R. Garnett, PharmD
FACING THE CHALLENGES OF EPILEPSY TREATMENT An interview with William R. Garnett, PharmD Dr William R. Garnett is Professor of Pharmacy and Neurology at the Virginia Commonwealth University/Medical College
More informationA study of Standard and New Antiepileptic Drugs SANAD-II
The SANAD II project is funded by the NIHR Health Technology Assessment Programme. Hospital Logo Address NIHR code A study of Standard and New Antiepileptic Drugs SANAD-II ADULT INFORMATION SHEET www.sanad2.org.uk
More informationSABRIL (vigabatrin) powder for oral solution and oral tablet Vigadrone (vigabatrin) powder for oral solution Vigabatrin powder for oral solution
Vigabatrin powder for oral solution Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationAdvances in the diagnosis and management of epilepsy in adults
n DRUG REVIEW Advances in the diagnosis and management of epilepsy in adults Diego Kaski MRCP, PhD and Charles Cockerell MD, FRCP SPL This drug review looks at the key issues in diagnosing epilepsy, initiating
More informationAnnex III. Amendments to relevant sections of the Product Information
Annex III Amendments to relevant sections of the Product Information Note: These amendments to the relevant sections of the Summary of Product Characteristics and package leaflet are the outcome of the
More informationSlide 1. Slide 2. Slide 3. Objectives. Why should we care about the elderly? Antiseizure Drugs in Elderly Patients
Slide 1 Antiseizure Drugs in Elderly Patients Angela Birnbaum, Ph.D. Professor Epilepsy Research and Education Program Center for Clinical and Cognitive Neuropharmacology College of Pharmacy University
More information